ライフサイエンスコーパス: serum hepatitis

1 association between TDAV infection and acute serum hepatitis.

2 anscription by serum HBV RNA, translation by serum hepatitis B core related antigen (HBcrAg), and the

3 Serum hepatitis B core-related antigen (HBcrAg) is one s

4 se in comparison of the rate of undetectable serum Hepatitis B deoxyribonucleic acid (HBV DNA) as the

5 tiviral activity as evidenced by the loss of serum hepatitis B e antigen and hepatitis B virus (HBV)

6 irologic response (defined by the absence of serum hepatitis B e antigen and serum HBV DNA) at week 5

7 BV) DNA in serum and 45 (87%) had detectable serum hepatitis B e antigen before treatment.

8 Geometric mean concentration (GMC) of serum hepatitis B surface antibodies (anti-HBs) and prop

9 trols, chronic HBV infection was assessed by serum hepatitis B surface antigen (HBsAg) and AFB1 expos

10 ion recipients of livers from donors without serum hepatitis B surface antigen (HBsAg) but with antib

11 luding the change from baseline to day 29 in serum hepatitis B surface antigen (HBsAg) concentration.

12 This study investigated the role of serum hepatitis B surface antigen (HBsAg) levels and est

13 V) preS/S gene variability has any impact on serum hepatitis B surface antigen (HBsAg) levels and to

14 The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during

15 participants, 603,585 had baseline data for serum hepatitis B surface antigen (HBsAg) status and wer

16 The patient is clinically normal, serum hepatitis B surface antigen negative at 10 months

17 on included the following: illicit drug use, serum hepatitis B surface antigen positive, grade 1 ence

18 smoking, elevated alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C viru

19 ex, smoking, serum alanine aminotransferase, serum hepatitis B surface antigen, anti-hepatitis C viru

20 of the post-LT cohort achieved undetectable serum hepatitis B virus (HBV) DNA (Roche Amplicor Monito

21 corresponds to the degree of suppression of serum hepatitis B virus (HBV) DNA achieved with therapy.

22 Hepatitis B e antigen (HBeAg) status and serum hepatitis B virus (HBV) DNA levels are major facto

23 ansferase levels (Group I) maintained higher serum hepatitis B virus (HBV) DNA levels but significant

24 ed alanine transaminase (ALT) levels and low serum hepatitis B virus (HBV) DNA predict a higher likel

25 percent, P=0.003), sustained suppression of serum hepatitis B virus (HBV) DNA to undetectable levels

26 Serum hepatitis B virus (HBV) DNA was detectable using b

27 Serum hepatitis B virus (HBV) DNA was detected by soluti

28 243; lamivudine, n = 164) were assessed for serum hepatitis B virus (HBV) DNA, alanine aminotransfer

29 RC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen

30 e replication and drug resistance of patient serum hepatitis B virus (HBV) populations can contribute

31 med to better characterize the repertoire of serum hepatitis B virus (HBV) RNAs during chronic HBV in

32 The serum hepatitis B virus (HBV) surface antigen (HBsAg) le

33 ed for HBsAg, hepatitis B e antigen (HBeAg), serum hepatitis B virus (HBV)-DNA levels, and anti-hepat

34 ears achieved the primary efficacy endpoint (serum hepatitis B virus [HBV] DNA <1,000 copies/mL and n

35 ts with chronic hepatitis B virus infection, serum hepatitis B virus DNA and liver biochemical test l

36 e monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referra

37 Patients not on treatment but with a serum hepatitis B virus DNA level >200,000 IU/mL during

38 rapy, compared with conventional measures of serum hepatitis B virus DNA.

39 of 10 g/d has been associated with increased serum hepatitis C viral RNA and aminotransferase levels,

40 Efficacy was assessed by measurements of serum hepatitis C virus (HCV) RNA and serum aminotransfe

41 saminase (ALT) concentration and decrease in serum hepatitis C virus (HCV) RNA concentration below th

42 and virological responses (percent negative serum hepatitis C virus [HCV] RNA) after treatment.

43 breakthrough/relapse patients (undetectable serum hepatitis C virus RNA after 24 weeks of peginterfe

44 irologic response (undetectable [<125 IU/mL] serum hepatitis C virus RNA at 24-week follow-up).

45 genotype 1 hepatitis C virus infection with serum hepatitis C virus RNA concentrations of at least 5

46 vel of serum aminotransferases, the level of serum hepatitis C virus RNA, and histologic necroinflamm

47 on the achievement of sustained clearance of serum hepatitis C virus RNA, which is influenced, in tur

48 s, with or without achieving an undetectable serum hepatitis D virus (HDV) RNA, as a marker of virolo